TNGX (Tango Therapeutics) ROCE % : -55.18% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tango Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2024 was -55.18%.

Tango Therapeutics ROCE % Historical Data

The historical data trend for Tango Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tango Therapeutics ROCE % Chart

Tango Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

-31.38

-18.60

-26.43

-30.96

-45.86

Tango Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial													-37.78	-46.95	-33.72	-40.32	-55.18

Tango Therapeutics ROCE % Calculation

Tango Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-145.595	/	( ( (402.567 - 45.938)	+	(316.492 - 38.17) )	/ 2 )
	=	-145.595	/	( (356.629	+	278.322)	/ 2 )
	=	-145.595	/	317.4755
	=	-45.86 %

Tango Therapeutics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-163.64	/	( ( (352.415 - 37.583)	+	(316.492 - 38.17) )	/ 2 )
	=	-163.64	/	( ( 314.832	+	278.322 )	/ 2 )
	=	-163.64	/	296.577
	=	-55.18 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Tango Therapeutics (NAS:TNGX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tango Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tango Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215

Website

https://www.tangotx.com

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Executives

Douglas Barry	officer: See Remarks	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Adam Crystal	officer: See Remarks	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Barbara Weber	director, officer: Chief Executive Officer	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Daniella Beckman	officer: Chief Financial Officer	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Mace Rothenberg	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Lesley Ann Calhoun	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
John B Ketchum	director	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc	director	201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p.	director	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p.	director	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116